Lucas D. Ward

Affiliations: 
2000-2004 University of Virginia, Charlottesville, VA 
 2004-2010 Columbia University, New York, NY 
 2010-2014 Massachusetts Institute of Technology, Cambridge, MA, United States 
 2015-2019 Amgen Inc., Thousand Oaks, CA, United States 
 2016-2016 deCode Genetics Inc 
 2019- Alnylam Pharmaceuticals 
Google:
"Lucas D. Ward"

Parents

Sign in to add mentor
Joel G. Belasco research assistant 2003 (Microtree)
Anne Beyer research assistant 2002-2003 UVA (Neurotree)
Virginia W. Cornish research assistant 2004 (Chemistry Tree)
Iva Susan Greenwald research assistant 2005 (GenetiTree)
Harmen J. Bussemaker grad student 2010 Columbia (Physics Tree)
Manolis Kellis post-doc 2010-2014 MIT
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Turk JR, Deaton AM, Yin J, et al. (2020) Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regulatory Toxicology and Pharmacology : Rtp. 104697
Nguyen PA, Born DA, Deaton AM, et al. (2019) Author Correction: Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nature Communications. 10: 2132
Nguyen PA, Born DA, Deaton AM, et al. (2019) Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nature Communications. 10: 1579
Deaton AM, Fan F, Zhang W, et al. (2018) Rationalizing secondary pharmacology screening using human genetic and pharmacological evidence. Toxicological Sciences : An Official Journal of the Society of Toxicology
Deaton AM, Sulem P, Nioi P, et al. (2018) A rare missense variant in associates with lower cholesterol levels. Communications Biology. 1: 14
Ward LD, Moffat GJ, Yuan J, et al. (2018) Comment on "Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors". Drug Safety
Fielden MR, Ward LD, Minocherhomji S, et al. (2017) Modernizing Human Cancer Risk Assessment of Therapeutics. Trends in Pharmacological Sciences
Jónsson H, Sulem P, Kehr B, et al. (2017) Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 549: 519-522
Jónsson H, Sulem P, Kehr B, et al. (2017) Whole genome characterization of sequence diversity of 15,220 Icelanders. Scientific Data. 4: 170115
Benonisdottir S, Oddsson A, Helgason A, et al. (2016) Epigenetic and genetic components of height regulation. Nature Communications. 7: 13490
See more...